Peter Higgins
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
698
Citations
27,069
Est. group size
~27
Recurring co-author estimate
Active years
48
Publishing since 1978
Typically publishes in teams of ~6 · 41% small-team papers (≤3 authors) · across 34 venues
- "Cut and Cover”: A case series of dual modality treatment with stricturotomy and stenting for inflammatory bowel disease related strictures
2025
- Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
The Lancet. Gastroenterology & hepatology · 2025
- EFFICACY AND SAFETY OF UPADACITINIB FOR ACUTE SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Inflammatory Bowel Diseases · 2025
- AOUSDOHtools: An R Package for Social Determinants of Health Survey data in the All of Us Research Program
The Journal of Open Source Software · 2025
- A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the Pouch
The American Journal of Gastroenterology · 2025
- EFFICACY AND SAFETY OF UPADACITINIB FOR ACUTE SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Gastroenterology · 2025
- AXL: A novel therapeutic target in IBD
Advances in pharmacology · 2024
- P120 Upadacitinib for moderate-to-severe ulcerative colitis: interim results from U-ACTIVATE phase III open-label extension
Poster presentations · 2024
- Tu1844 MAGNITUDE OF SARS-COV-2 SPIKE ANTIBODY LEVEL FOLLOWING VACCINATION IS NOT ASSOCIATED WITH RISK OF DEVELOPING SYMPTOMATIC COVID-19 AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Gastroenterology · 2024
- Humoral immune response and safety of SARS‐CoV‐2 vaccination in very early onset inflammatory bowel disease
Journal of Pediatric Gastroenterology and Nutrition · 2024
- Risankizumab for Ulcerative Colitis
JAMA · 2024
- User guide for Social Determinants of Health Survey data in the <i>All of Us</i> Research Program
Journal of the American Medical Informatics Association · 2024
- Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials
Inflammatory Bowel Diseases · 2024
- Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies
Crohn s & Colitis 360 · 2024
- Risankizumab Is Effective for The Management of Crohn’s Disease of the Pouch
Inflammatory Bowel Diseases · 2024
- Gastroenterology×101
- Birds of the World×100
- Inflammatory Bowel Diseases×41
- Journal of Crohn s and Colitis×31
- The American Journal of Gastroenterology×28
- Brian Gutermuth
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Jeffrey Berinstein
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Dustin Romain
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Matthew Bohm
Biochemistry, Genetics and Molecular Biology · Indiana University
- Akbar K. Waljee
Biochemistry, Genetics and Molecular Biology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile